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Obesity has been recognized as one of the most important risk factors for a variety of chronic diseases, such as diabetes,
hypertension/cardiovascular diseases, steatosis/hepatitis, and cancer. Keishibukuryogan (KBG, Gui Zhi Fu LingWan in Chinese) is
a traditional Chinese/Japanese (Kampo) medicine that has been known to improve blood circulation and is also known for its anti-
inflammatory or scavenging effect. In this study, we evaluated the effect of KBG in two distinct rodent models of obesity driven by
either a genetic (SHR/NDmcr-cp rat model) or dietary (high-fat diet-induced mouse obesity model) mechanism. Although there
was no significant effect on the body composition in either the SHR rat or the DIO mouse models, KBG treatment significantly
decreased the serum level of leptin and liver TG level in the DIO mouse, but not in the SHR rat model. Furthermore, a lower
fat deposition in liver and a smaller size of adipocytes in white adipose tissue were observed in the DIO mice treated with KBG.
Importantly, we further found downregulation of genes involved in lipidmetabolism in the KBG-treated liver, along with decreased
liver TG and cholesterol level. Our present data experimentally support in fact that KBG can be an attractive Kampo medicine to
improve obese status through a regulation of systemic leptin level and/or lipid metabolism.
1. Introduction
Obesity has been recognized as one of the most important
risk factors for a variety of chronic diseases, such as diabetes,
hypertension/cardiovascular diseases, steatosis/hepatitis, and
cancer [1, 2]. Accumulating evidence indicates that the patho-
genesis of obesity-related metabolic dysfunction involves the
development of a systemic low-grade inflammatory state and
a deregulated lipid metabolism. Furthermore, it has become
apparent that adipose tissue can be a source of secreted
regulatory proteins called adipokine which act as modulators
of metabolic and immunological processes [3].
Among those, an adipokine leptin is known as the prod-
uct of the obese gene (ob) that was identified in spontaneous
obese ob/ob mice [4]. Leptin regulates feeding behavior;
therefore rodents genetically lacking leptin or its receptor
show hyperphagia and subsequently develop obesity and
insulin resistance. Although leptin itself showed an improv-
ing effect in metabolic dysfunction, the blood leptin levels
have been known to correlate with adipose tissue mass, and
such pathologically elevated levels of leptin did not induce
anorexia in obese humans and rodents, therefore suggesting
that leptin resistance can be common in obesity [5].
Traditional Chinese/Japanesemedicine has a long history
and has contributed to the prevention and treatment of vari-
ous diseases. Keishibukuryogan (KBG, Gui Zhi Fu LingWan
in Chinese) is one of the formulations in the ancient Chinese
medicine and is composed of five crude drugs: Cinnamomi
Cortex, Poria cocos, Moutan Cortex, Persicae Semen, and
Paeoniae Radix. While KBG has been originally used for the
treatment of gynecological diseases, it has also been used for
the treatment of blood hemorheology, platelet aggregation,
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Figure 1: Analysis by three-dimensional HPLC of major chemical compounds included in keishibukuryogan extract.
and inflammation. Previous preclinical studies revealed that
KBG inhibits the development of atherosclerosis and pre-
vents nonalcoholic steatohepatitis in cholesterol-fed rabbits
[6, 7], improves endothelial function in hypertensive rats [8],
shows protective effects on vascular injury in diabetic rats [9],
and reduces oxidative stress by hyperglycemia in WBN/Kob
rats [8]. Importantly, even in a clinical study, long-term
KBG treatment improved vascular endothelial function and
resulted in the prevention of atherosclerosis [10]. Collectively,
the preclinical and clinical evidence strongly suggest that
KBG can be generally useful for the prevention and treatment
of tissue damage caused bymetabolic dysfunction through its
anti-inflammatory and/or antioxidative effect.
In order to explore the effect of KBG on obesity, we tested
the therapeutic effect of KBG on two preclinical rodent obe-
sity models driven by either a genetic or dietary mechanism.
While the SHR/NDmcr-cp (SHR) rat model has been known
to develop metabolic disorders due to its genetic deficiency
in leptin receptor [11], the high-fat diet-induced obesity
(DIO) model in C57BL/6 mice has been widely recognized
as an obesity model driven by a dietary mechanism [12, 13].
Although there was no obvious effect in the body composi-
tion of obese animals, KBG treatment significantly decreased
the serum level of leptin and liver lipid content in the DIO
mouse, but not in the SHR rat model. In concert with
its lipid-lowering effect, KBG treatment improved steatosis
and adipocyte enlargement in the DIO mouse and further
Table 1: Components of the keishibukuryogan formula.
Crude drugs Weight ratio (g)
Cinnamomi Cortex 3.0
Poria cocos 3.0
Moutan Cortex 3.0
Persicae Semen 3.0
Paeoniae Radix 3.0
downregulated the expression of genes involved in lipid
metabolism (PPAR𝛾, SERBP1) in the KBG-treated liver. Our
presented data experimentally support that KBG can be an
attractive Chinese/Japanese traditional medicine to improve
obese status through the regulation of systemic leptin levels
and/or liver lipid metabolism.
2. Materials and Methods
2.1. Preparation of Keishibukuryogan (KBG). The extract of
KBG was kindly provided by TSUMURA & Co. (TJ-25,
Tokyo). The prescription of crude drugs constituting KGB
(Table 1) was added to water and extracted at 100∘C for 1 hr.
The water extract was filtered and spray-dried to obtain a
dry extract powder. The 3D-HPLC chart of the KBG extract
provided by TSUMURA & Co. is shown as in Figure 1 for
quality reference.
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Figure 2: Effect of KBG on body weight changes and tissue weight in obesity models. (a, b) SHR rats were administered with control water
or KBG (500mg/kg, p.o., daily) for 8 weeks. Body weight changes (a) or tissue weight (b, liver and fat, at 8 weeks after daily treatment) of
SHR rats is shown. (c, d) C57BL/6 mice were fed with normal diet (ND) or high-fat diet (HFD) for 10 weeks and then administered with
control water or KBG (500mg/kg, p.o., daily) for 12 weeks under the same feeding condition. After 8 weeks of control or KBG treatment,
mice fed with HFD were changed to ND until the termination of experiment with maintaining KBG treatment for another 4 weeks. Body
weight changes (a) or tissue weight (b, liver and fat at 12 weeks after daily treatment) of DIO mouse is shown. Data are mean ± SEM (𝑛 =
7–15).
2.2. Animal Experiments. SHR/NDmcr-cp (SHR) rats (16
weeks old, male) and C57BL/6J mice (5 weeks old, male)
were purchased from Japan SLC Inc. (Hamamatsu, Japan). All
experiments were approved by and performed according to
the Guidelines of the Care and Use of Laboratory Animals of
the University of Toyama. For the spontaneously developing
genetic obesity model, the SHR rats were housed for 9 weeks
feeding on normal chow (LaboMR Stock, Nosan, Yokohama,
Japan) before being subjected to KBG treatment. A group of
SHR rats was administered KBG (orally with gavage, daily at
500mg/kg dose) or control water for 8weeks and sacrificed to
collect tissue and serum samples. For the diet-induced obesity
(DIO)mousemodel, a group of C57BL/6J mice were fed with
high-fat diet (HFD, D12492, Research Diets Inc., NJ, USA)
for 10 weeks to develop chronic obesity. A separate group of
mice was fed a normal diet (ND, D12450B, Research Diets
Inc.) as a control. After 10 weeks of high-fat diet feeding, the
DIO mice were divided into two groups with similar average
of body weight and treated with either KBG (orally with
gavage, daily at 500mg/kg dose) or control water for 12weeks.
Upon 8weeks’ treatmentwithKBGorwater, an interimblood
sample collectionwas conducted and then allmicewere given
normal chow (Labo MR Stock) for another 4 weeks. On
termination of the experiment, blood and tissue samples
were collected. Body weight and food intake were monitored
weekly.
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2.3. SerumMeasurements. Serum leptin or insulin levelswere
determined by using a specific enzyme-linked immunosor-
bent assay (ELISA) according to the manufacturer’s instruc-
tion.The ELISA kit for rat and mouse leptin (Lbis Leptin-Rat
kit or Lbis Leptin-Mouse kit) and rat insulin kit (Lbis insulin-
Rat kit) were purchased from Shibayagi Co. Ltd. (Shibukawa,
Japan.) kit. Themouse insulin ELISA kit was purchased from
Morinaga & Co. (Yokohama, Japan).
2.4. Liver Lipid Content Measurements. The liver tissues were
weighed and homogenized in sodium chloride buffer and
then the homogenates were extracted with 5mL of chloro-
form and methanol (2 : 1, vol/vol) [14]. The chloroform layers
were dried and then triglyceride (TG), total cholesterol (cho-
lesterol), and free fatty acids (FFA) were measured by using
LabAssay Cholesterol kit, LabAssay triglyceride kit, and
LabAssay NEEA kit (Wako Chemical, Osaka, Japan).
2.5. Histological Analysis. Liver and epididymal adipose tis-
sues were collected upon termination of the experiments and
immediately fixed with 4% PFA for 1-2 days. The fixed tissue
sample was then sliced sequentially into sections 3–5mm in
thickness. Representative sections of the liver or fat tissue 2-
3mm thick were selected and embedded in paraffin for rou-
tine histopathological analysis with hematoxylin and eosin
(H&E) staining.
2.6. Real-Time RT-PCR for Quantitative Assessment of mRNA
Expression. Total RNAswere prepared using the RNeasy Plus
Mini kit (QIAGEN, Hilden, Germany). The expression level
of targeted mRNAs was normalized to mGapdh mRNA by
using One Step SYBR PrimeScript RT-PCR kit II (Takara,
Kyoto, Japan). The primers used in this experiment are listed
in Table 2.
2.7. Statistics. Statistical analysis was performed with JMP
(SAS Institute Japan, Tokyo). Data were expressed as mean ±
SEM. One-way ANOVA followed by Dunnett’s test was used
to determine the statistical differences among groups.
3. Results
3.1. Effect of KBG on Body Weight Changes and Tissue Weight
in Obesity Models. In order to examine the therapeutic
efficacy of KBG in genetic or dietary obesity models, we
employed an SHR rat model or a DIO mouse model, respec-
tively. As shown in Figures 2(a) and 2(b), KBG treatment did
not affect either body weight or tissue weight (liver and epi-
didymal fat) in the SHR rat model. In the DIOmouse model,
C57BL/6 mice were fed with HFD for 8 weeks before being
subjected to KBG treatment and significantly gained body
weight, compared with the ND group. Similar to the SHR rat
model, KBG treatment did not affect the body weight gain in
the chronic DIO mouse model (Figure 2(c), up to 8 weeks).
We then tested the efficacy of KBG in combination with diet
modification by feeding mice a standard diet for subsequent
4 weeks from 8-week time point. Even in this condition, we
did not see any significant effect on either bodyweight change
or tissue weight (liver and epididymal fat) upon termination.
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Figure 3: Effect of KBG on serum levels of leptin and insulin in
obesity models. (a, b) SHR rats were administered with control
water or KBG (500mg/kg, p.o., daily) for 8 weeks. Serum samples
were collected upon the termination and levels of leptin (left) or
insulin (right) were measured. (b, c) C57BL/6 mice were fed with
normal diet (ND) or high-fat diet (HFD) for 10 weeks and then
administered with control water or KBG (500mg/kg, p.o., daily) for
12 weeks under the same feeding condition. After 8 weeks of control
or KBG treatment, mice fed with HFD were changed to ND until
the termination of experiment with maintaining KBG treatment for
another 4 weeks. Serum samples were collected before the time for
food changing (b) or upon the termination (c) and levels of leptin
(left) or insulin (right) weremeasured by using specific ELISA assay.
Data are mean ± SEM (𝑛 = 7–15). ∗𝑃 < 0.005; ∗∗𝑃 < 0.001.
Collectively, KBG did show any dynamic efficacy on either
body or tissue weight gain in either genetic or dietary obesity
model.
3.2. Effect of KBG on Serum Levels of Leptin and Insulin in
Obesity Models. We then investigated whether KBG treat-
ment affects the obesity-associated serum biomarkers. While
KBG treatment did not show any significant effect on the
serum levels of leptin in the SHR ratmodel (Figure 3(a)), DIO
mice treated with KBG showed a significantly lower level of
serum leptin, both in chronic disease state (Figure 3(b)) and
in combination with diet modification (Figure 3(c)). Neither
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Table 2: Sequences of the primers used in real-time PCR of the mouse tissue.
Gene Forward primer Reverse primer
PPAR𝛾 GAACCTGCATCTCCACCTTATT TGGAAGCCTGATGCTTTATCC
PPAR𝛼 CGGTGTGTATGAAGCCATCT TAAGGAACTCGCGTGTGATAAA
SREBP-1 CATCGACTACATCCGCTTCTT CACCAGGTCCTTCAGTGATTT
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Figure 4: Effect of KBG on liver lipid levels in obesity models. (a) SHR rats were administered with control water or KBG (500mg/kg, p.o.,
daily) for 8 weeks. Liver tissue samples were collected upon the termination and levels of triglyceride (TG, left), total cholesterol (cholesterol,
middle), and free fatty acid (FAA, right) were measured. (b) C57BL/6 mice were fed with normal diet (ND) or high-fat diet (HFD) for 10
weeks and then administered control water or KBG (500mg/kg, p.o., daily) for 12 weeks under the same feeding condition. After 8 weeks of
control or KBG treatment, mice fed with HFDwere changed to ND until the termination of experiment with maintaining KBG treatment for
another 4 weeks. Liver tissue samples were collected upon the termination and levels of triglyceride (TG, left), total cholesterol (cholesterol,
middle), and free fatty acid (FAA, right) were measured. Data are mean ± SEM (𝑛 = 7–15). ∗𝑃 < 0.005.
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Figure 5: Histopathological evaluation of fat and liver tissue in DIO mice. C57BL/6 mice were fed with normal diet (ND) or high-fat diet
(HFD) for 10 weeks and then administered with control water or KBG (500mg/kg, p.o., daily) for 12 weeks under the same feeding condition.
After 8 weeks of control or KBG treatment, mice fed with HFD were changed to ND until the termination of experiment with maintaining
KBG treatment for another 4 weeks. (a) Representative images (×200) of H&E staining of liver (upper panels) and white adipose tissue (lower
panels) of DIO mice are shown. (b) Steatosis scores of DIO mice. N.D.: not detected. (c) Observed number of adipocyte counts of WAT in
DIO mice. Data are mean ± SEM (𝑛 = 7–15). ∗∗𝑃 < 0.001.
the SHR rats nor the DIOmice treated with KBG showed any
significant alteration in their serum insulin level (Figure 3).
3.3. Effect of KBG on Lipid Metabolism in Obesity Models. To
further explore the therapeutic benefit of KBG in obesity, we
examined the effect of KBGon the expression of liver lipids in
both SHR rats and DIO mice. While KBG did not show any
significant effect on liver content of TG, cholesterol, and FFA
in the SHR rat (Figure 4(a)), the liver TG and cholesterol level
(but not FFA level) of the KBG-treated DIOmice were signif-
icantly lower than those of the control group (Figure 4(b)).
In concert with such a reduction in the liver lipid contents,
we observed less adipocyte accumulation in the liver of
DIO mice treated with KBG (Figure 5(a), upper panels) and
indeed the steatosis score was significantly lower in DIO
mice treated with KBG (Figure 5(b)). Furthermore, the size
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Figure 6: Effect of KBG on obesity-associated gene expression in
liver tissue of DIO mice. C57BL/6 mice were fed with normal diet
(ND) or high-fat diet (HFD) for 10 weeks and then administered
with control water or KBG (500mg/kg, p.o., daily) for 12 weeks
under the same feeding condition. After 8 weeks of control or
KBG treatment, mice fed with HFD were changed to ND until
the termination of experiment with maintaining KBG treatment
for another 4 weeks. Liver tissue samples were collected upon the
termination and the relative expression of obesity-associated genes
(PPARg, PPARa, and Srebf1) was determined by RT-PCR and shown
as relative expression to HFD group (HFD = 1). Data are mean ±
SEM (𝑛 = 7–15). ∗∗𝑃 < 0.001.
of adipocytes in white adipose tissue, which was enlarged
in DIO mice, was relatively smaller with KBG treatment
(Figure 5(a), lower panels) as seen in the increased number
of adipocytes on histological examination (Figure 5(c)). We
then examined the effect of KBG on the mRNA expression of
molecules associated with lipid metabolism in liver to under-
stand the potential molecular mechanism that underlies the
control of lipid metabolism in KBG-treated DIO mice, by
using quantitative real-time PCR. As shown in Figure 6, we
found that the mRNA expressions of PPAR𝛾 and SREBP1 in
the liver were significantly decreased by KBG treatment in
DIO mice.
4. Discussion
KBG is a traditional Kampo medicine that has been widely
used for improving blood circulation and is also known for
its anti-inflammatory or scavenging effect, hence its relevance
to obesity being expected [8, 10]. In this study, we employed
two distinct obesity preclinical animal models, driven by a
genetic or dietary mechanism, to test the therapeutic efficacy
of KGB. While KBG did not show any significant impact on
body composition of either obesity model, the serum level
of leptin and the liver TG contentwere significantly decreased
by KGB treatment in the diet-induced obesity mouse model.
Considering these results, KBG is presumably not actively
effective in body composition in diet-induced obesity but
rather effective in modulating the metabolic status of
adipocytes or lipid metabolism. Indeed, lower liver lipid con-
tents and lower liver fat deposition were observed in DIO
mice treated with KGB. Furthermore, the size of adipocytes
in white adipose tissue wasmuch smaller inDIOmice treated
with KBG. As such differences were not observed in DIO
mice maintained on high-fat diet feeding conditions solely
treated with KBG (data not shown), we speculate that the
antiobesity effect of KBG may require the presence of diet
therapy. Although the exact mechanism of the lipid-lowering
effect of KBG in vivo has not been clarified yet, we observed
the alteration in the liver mRNA expression of molecules
associated with lipid metabolism (PPAR𝛾 and SREBP1) in
DIO mice treated with KGB [15–17]. Considering the result
that KGB did not have an effect on much of those serum
parameters and liver lipid contents in the leptin-deficient
SHR rat model, we also presume that the lipid-lowering effect
of KGB may be mediated by regulating the systemic leptin
level. As leptin has been widely known as a potent lipid-
lowering adipokine and considered as an important factor in
preventing cellular lipotoxicity and insulin resistance [5, 18],
the modulating effect of KBG or its active component in
leptin may reside at least partially in themechanism of action
for the lipid-lowering effect of KBG. In this context, it would
be important to further explore any correlation between the
clinical response to KBG and leptin resistance in obesity
patients.
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